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E-mail: vhsato@kenroku.kanazawa-u.ac.jpMembrane-type matrix metalloproteinase-1 (MT1-MMP) mediates
cleavage of not only MMP-2 ⁄gelatinase A for activation, but also a
variety of substrates including type I collagen (reviewed in Cancer
Sci 2005; 96: 212–7). MMP-2 activation involves tissue inhibitor of
MMP (TIMP)-2 as a bridging molecule between MT1-MMP and pro-
MMP-2. Thus, net activity of MT1-MMP and MMP-2 is regulated in
a complex manner depending on TIMP-2 concentration. During
invasive growth of tumor cells in type I collagen matrix, MT1-MMP
initiates denaturation of collagen into gelatin, which is subse-
quently digested further by MMP-2 adjacent to MT1-MMP. Coordi-
nate action of MT1-MMP and MMP-2 may facilitate pericellular
proteolysis, and enhance not only tumor invasion/migration but
also cell growth. Tetraspanins as binding proteins of MT1-MMP
regulate MT1-MMP subcellular localization and compartmentaliza-
tion, leading to efficient MMP-2 activation and proteolysis coupled
with cellular function. (Cancer Sci 2010; 101: 843–847)
T he major physiological role of matrix metalloproteinases(MMPs) is for homeostatic regulation of the extracellular
environment, not simply to degrade matrix as their name sug-
gests. MMPs are overexpressed in various human malignan-
cies.(1,2) The expression of MMPs is specifically regulated at the
level of transcription. However, the catalytic activity of these
proteinases is further controlled at additional levels, including
activation of the pro-enzyme and inhibition of the active enzyme
by specific inhibitors.(3–5) Because MMPs including MMP-2
(gelatinase A ⁄72-kDa type IV collagenase) are secreted as an
inactive zymogen, activation is another key regulatory step for
MMP function in vivo. The molecular environments in tumors
appear conducive to MMP activation. Activated MMP-2 was
specifically observed in a variety of tumor tissues, suggesting
the presence of pro-MMP-2 activator(s) in tumor tissues.(6–8)
This led to the identification of the first membrane type-MMP
(MT1-MMP) as an activator of pro-MMP-2 expressed on the
surface of tumor cells.(8) In addition to pro-MMP-2 cleavage for
activation, MT1-MMP was shown to cleave variety of sub-
strates, not only extracellular matrix (ECM) macromolecules,
but also various biologically important molecules (reviewed in
references9,10).
Interaction of MT1-MMP with TIMP
To date, six MT-MMPs have been identified by cDNA cloning,
and the proteolytic activation of pro-MMP-2 was shown experi-
mentally for all MT-MMPs.(11–14) MT-MMPs are unique in that
they contain a furin recognition motif between the pro- and cata-
lytic domains, and are processed by proprotein convertases suchdoi: 10.1111/j.1349-7006.2010.01498.x
ª 2010 Japanese Cancer Associationas furin in the secretory pathway.(15) In contrast to secretory
form of MMPs, MT-MMPs are presented to the cell surface in
active form. MT1-MMP is inhibited by endogenous inhibitors
TIMP-2, -3, and -4, but not by TIMP-1.(16,17) This TIMP-1
insensitive nature is common to all MT-MMPs except for MT4-
MMP.(18) MT1-MMP causes a rapid auto-degradation in the
absence of its inhibitor to produce a 44-kDa form.(19) Due to
rapid turnover rate of active MT1-MMP, its concentration on
cell surface is very low, and the active form of MT1-MMP pre-
dominantly localizes on the cell surface by forming a complex
with the inhibitor (Fig. 1). TIMP-2 is the most common inhibi-
tor of MT1-MMP, and MT1-MMP ⁄TIMP-2 complex serves as a
receptor for pro-MMP-2. Administration of the synthetic revers-
ible inhibitor of MMP induces accumulation of MT1-MMP on
the cell surface, which exerts enzyme activity at a burst by the
removal of the inhibitor.(20)
Implications from MMP-deficient mice
MT1-MMP is the most common physiological activator of pro-
MMP-2, and the MT1-MMP-deficient mouse produces only a
faint level of active MMP-2.(21,22) MT1-MMP-null mice have
severe defects in skeletal development and angiogenesis and die
within several weeks after birth, suggesting an essential role for
MT1-MMP in the process of angiogenesis and bone
growth.(21,22) This phenotype is much more severe than that seen
in the MMP-2-deficient mice, which have smaller stature,
blunted tumor-related angiogenesis, and abnormal lung alveolar-
ization.(23) A hereditary deficiency in MMP-2 has been
described in Middle Eastern families who develop a vanishing
bone disorder.(24,25) Thus, MT1-MMP functionality significantly
exceeds MMP-2 activation in development. However, MT1-
MMP and MMP-2 double-knockout mice show more severe
phenotype than MT1-MMP-deficient mice, and die immediately
after birth with respiratory failure, abnormal blood vessels, and
immature muscle fibers reminiscent of central core disease.(26)
This indicates that residual MMP-2 activation in MT1-MMP-
null mice contributes to prolonged survival by partly complicat-
ing MT1-MMP functions in development. MMP-2 degrades
types IV and V collagens, gelatins, laminin, fibronectin, and
elastin.(27,28) From the analysis of MMP-2-deficient mice,
MMP-2 does not seem to be indispensable in development,
although it partially complicates MT1-MMP. However, MMP-2
plays critical roles in pathological conditions including tumor
growth.(23) For instance, angiogenesis and tumor growth are sub-











Fig. 1. Fate of membrane-type matrix metallopro-
teinase-1 (MT1-MMP) on the cell surface. MT1-MMP
on cell surface rapidly turns over by auto-degra-
dation or clathrin-dependent internalization. The
internalized MT1-MMP is recycled or degraded in
lysozome. MT1-MMP inactivated by tissue inhibitor
of MMP (TIMP)-2 avoids auto-degradation, and
accumulates on the cell surface. Accumulated
MT1-MMP ⁄ TIMP-2 complex serves as a receptor for
pro-MMP-2. It should be noted that concentration
of active MT1-MMP on cell surface is quite low due
to rapid auto-degradation, and only TIMP-2-inacti-
vated MT1-MMP accumulates.mice (also MMP-9-null mice) have extremely low incidences of
cardiac rupture after acute myocardial infarction.(29,30)
Mechanism of MMP-2 activation by MT1-MMP
Accumulated lines of evidence have demonstrated that MMP-2
is always activated in tumor tissues, in which MT1-MMP is
expressed.(8,31,32) Furthermore, MT1-MMP expression and
MMP-2 activation levels are well co-related and closely associ-
ated with invasiveness and malignancy of tumors, suggesting
that MT1-MMP is as critical a factor for tumor invasion and
metastasis as MMP-2 activator.(31,32) However, due to the com-
plex MMP-2 activation process, the enzyme activity of MMP-2
and its possible contribution to tumor malignancy remain
unclear.
The MT1-MMP mechanism of pro-MMP-2 activation has
been well studied and partially defined.(33–35) The suggested
model implicates TIMP-2 as a bridging molecule, tethering
pro-MMP-2 through binding between the COOH-terminal ends
of pro-MMP-2 and TIMP-2 and binding between the NH2-ter-











844of pro-MMP-2 is cleaved by an adjacent TIMP-2–free MT1-
MMP between Asn37 and Leu38, generating an activated inter-
mediate form that is further processed to the fully activated form
by an intermolecular auto-cleavage when an intermediate form
is present at a sufficiently high concentration at the cell surface.
Pro-MMP-2 activation was expected to occur only at low TIMP-
2 concentrations relative to MT1-MMP, which would permit the
availability of active MT1-MMP to process the proMMP-2
bound in the ternary complex.(19,34–39) Actually MT1-MMP
auto-degradation is suppressed in the presence of TIMP-2, and
MT1-MMP ⁄TIMP-2 complex accumulates on cell surface.(40)
The accumulated MT1-MMP ⁄TIMP-2 complex serves as a
receptor for pro-MMP-2, and the receptor-bound pro-MMP-2 is
cleaved for activation by TIMP-2-free active MT1-MMP. In
order to induce efficient pro-MMP-2 processing, the molar ratio
of MT1-MMP ⁄TIMP-2 complex to TIMP-2-free MT1-MMP is
quite high (Fig. 3). Thus, MT1-MMP cannot cleave other direct
substrates at the TIMP-2 level that induces efficient pro-MMP-2
processing.(40,41) Furthermore, MMP-2 activated by MT1-MMP
at TIMP-2 concentration to induce most efficient pro-MMP-2
processing is inactive. The TIMP-2 concentration to produceFig. 2. Tissue inhibitor of MMP (TIMP)-2 concentra-
tion dictates substrate choice of membrane-type
matrix metalloproteinase-1 (MT1-MMP). Left, MT1-
MMP forms a complex with TIMP-2, and the
complex serves as a receptor for pro-MMP-2. Pro-
MMP-2, which binds to MT1-MMP ⁄ TIMP-2 complex
is then processed by the neighboring TIMP-2-free
MT1-MMP. The processed MMP-2 is inactivated by
TIMP-2 depending on its concentration. Right,
under TIMP-2-free condition, MT1-MMP directly
cleaves its own substrates, such as extracellular
matrix components, cell-surface molecules and so
on.
doi: 10.1111/j.1349-7006.2010.01498.x
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Fig. 3. Schematic illustration of tissue inhibitor of MMP (TIMP)-2-
regulated membrane-type matrix metalloproteinase-1 (MT1-MMP) and
MMP-2 activities. The level of active MT1-MMP and the ratio between
MT1-MMP of TIMP-2 complex and TIMP-2-free (active) in the cells
expressing MT1-MMP and different levels of TIMP-2 are schematically
illustrated. The level of MMP-2 processed by these cells is also shown,
which includes TIMP-2-free and TIMP-2-bound forms. In the absence
of TIMP-2, MT1-MMP activity is the highest, and decreases
proportionally to the TIMP-2 level. MMP-2 activated under a low
TIMP-2 level is free from TIMP-2, and shows the highest activity.
MMP-2 is processed most effectively at medium level of TIMP-2, in
which most of MT1-MMP serves as a receptor for pro-MMP-2 by
binding with MT1-MMP and processed MMP-2 is inactivated by TIMP-
2. MMP-2 processing is blocked when MT1-MMP is all bound by a
high level of TIMP-2. MSP-TIMP-2 does not affect MT1-MMP activity,
and generates a maximum level of processed MMP-2 which is free
from TIMP-2.TIMP-2-free active MMP-2 is restricted to a narrow range at a
low TIMP-2 concentration.(41,42)
The above observation and interpretation were confirmed by
using an artificial receptor for pro-MMP-2 (MSP-TIMP-2),
which exposes the TIMP-2 COOH-terminal domain on the cell
surface (Fig. 4).(41) Since MSP-TIMP-2 does not have an MMP-
inhibition function, the MT1-MMP level required to generate
active MMP-2 with MSP-TIMP-2 is much lower than that with
TIMP-2. This indicates that in the process of TIMP-2-mediated
pro-MMP-2 activation by MT1-MMP, the majority of MT1-
MMP functions as a receptor for pro-MMP-2 by making a com-
plex with TIMP-2. Only a minor part of MT1-MMP is free from
TIMP-2 and cleaves pro-MMP-2 in a tri-molecular complex.
Thus, MT1-MMP is unable to cleave direct substrates
effectively at TIMP-2 concentration to induce the most efficient
pro-MMP-2 processing. COS-1 cells synthesize relatively higher
concentration of TIMP-2 than 293T cells,(14) and MT1-MMP
exogenously expressed in COS-1 cells processes pro-MMP-2









Fig. 4. Artificial receptor for pro-matrix metallopro
teinaise-2 (MMP-2) (MSP-TIMP-2). (a) MSP-TIMP-2
consists of the transmembrane domain of type II
transmembrane protein mosaic serine ptotease
(MSP) and tissue inhibitor of MMP (TIMP)-2. Pro-
MMP-2 binds to the C-terminus of MSP-TIMP-2. (b)
Left, MSP-TIMP-2-expressing HT1080 cells generate
more active MMP-2 than mock cells. Right, MSP-
TIMP-2-expressing cells were cultured in collagen
gel, which caused intensive degradation of collagen
gel. Dotted line, border of collagen gel. Mag-
nification, ·100.
Sato and Takinostrates less effectively. Furthermore, MMP-2 activated by MT1-
MMP in COS-1 cells shows a poor enzyme activity (H.Sato,
Y. Okada and M. Seiki, unpublished data, 1994).
MT1-MMP turns over very rapidly due to autolysis if not
inactivated ⁄ stabilized by TIMP-2. The time course of MT1-
MMP production and its binding to TIMP-2 on the cell surface
is a critical factor; however, this still remains unsolved. The
cell-surface concentration of MT1-MMP stabilized by TIMP-2
is regulated by clathrin-dependent internalization (Fig. 1). Fur-
thermore, cell-surface MT1-MMP is regulated temporally and
spatially on the cell surface through the interaction with various
binding molecules including tetraspanins, which will be
discussed below. It should be noticed that such a dynamic cell-
surface event may not be interpreted simply in a static stoichi-
ometry, and further analysis is required.
TIMP-2-independent MMP-2 activation
Miyamori et al. reported that tight junction protein claudin
mediates the TIMP-2-independent MMP-2 activation pathway
by not only MT1-MMP but by other MT-MMPs.(14) Claudin
recruits MT-MMP and MMP-2 at a tight junction to achieve ele-
vated focal concentrations, and consequently enhances activa-
tion of pro-MMP-2. Among MT-MMP family members, only
MT1-MMP can accumulate on the cell surface through the com-
plex formation with TIMP-2, and serves as a receptor for pro-
MMP-2 (T. Takino and H. Sato, unpublished data, 2001). An
artificial receptor for pro-MMP-2 (MSP-TIMP-2) substitutes for
MT-MMP ⁄TIMP-2 complex, and induces activation by all MT-
MMPs except for MT4-MMP.(41) MT2-MMP was shown to
induce pro-MMP-2 activation in cells derived from TIMP-2-
deficient mice.(43,44) Pro-MMP-2 associates with TIMP-2-defi-
cient cells through the hemopexin domain, and is processed by
MT2-MMP.(43) Pro-MMP-2 receptor in TIMP-2-deficient cells
has not been identified, which cooperates with only MT2-MMP
but not MT1-MMP for activation. In any case, all MT-MMPs
can functionally cleave pro-MMP-2 for activation, but only
MT1-MMP ⁄TIMP-2 complex serves as an efficient receptor for
pro-MMP-2 activation (T. Takino and H. Sato, unpublished
data, 2001).
Coordinate action of MMP-2 and MT1-MMP
The HT1080 fiborosarcoma cell line expresses MT1-MMP, and
produces active MMP-2. MT1-MMP plays a pivotal role in
invasive growth in collagen gel, but the role of MMP-2 still
remains unclear. Expression of an artificial receptor for
pro-MMP-2 MSP-TIMP-2 in HT1080 cells enhances activation
of MMP-2 on the cell surface, and results in drastic degradation
of collagen gel, which never takes place by overexpression of
MT1-MMP or MMP-2 alone (Fig. 4b).(41) A possible explana-
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a collagenase cleaves type I collagen to initiate denaturation into
gelatin, which is subsequently digested to pieces by MMP-2
gelatinase. Unlike TIMP-2, MSP-TIMP-2 induces gelatinase
(MMP-2) activity without loss of collagenase (MT1-MMP)
activity, and its coordinate action may result in the excessive
melting of collagen gel. TIMP-2 regulates the balance between
MT1-MMP and MMP-2 activity depending on its concentration.
HT1080 cells produce a low level TIMP-2, and express both
active MT1-MMP and MMP-2 as shown in Figure 4, which
may coordinately contribute to the invasive character of
HT1080 cells. In fact, down-regulation of either MT1-MMP or
MMP-2 expression suppresses invasive growth of HT1080 cells
in collagen gel (T. Takino and H. Sato, unpublished data, 2004).
MMP-2 activated through MT1-MMP ⁄TIMP-2 complex as a
receptor remains on the receptor. MT1-MMP stimulates inte-
grin-mediated extracellular signal-regulated kinase (ERK) acti-
vation by enhancing the turnover rate of focal adhesions on
fibronectin or collagen.(45,46) MMP-2 activated by MT1-MMP
co-operates with MT1-MMP for ERK activation.(41) Recently,
Kenny et al. showed, using small-interfering RNA and neutral-
izing antibody targeting MMP-2, that MMP-2 plays an essential
role in tumor growth and metastasis in nude mice model in ovar-
ian cancer cells.(47) MMP-2 enhances peritoneal adhesion of
ovarian cancer cells through cleavage of fibronectin and vitro-
nectin into small fragments, and increases the binding of cells to
these fragments and their receptors, a5b1 and aVb3 integrin.
Tetraspanins as regulators of MT1-MMP. Tetraspanins are
attracting attention as binding proteins of MT1-MMP, which
regulate subcellular localization and compartmentalization of
MT1-MMP and consequent MT1-MMP activities.(48,49) Tetra-
spanins of integral membrane proteins with four predicted trans-
membrane domains comprise a large group of ubiquitously
expressed proteins (33 human members). Direct association of
MT1-MMP with a tetraspanin family member CD63 was first
reported by Takino et al.(50) CD63 was shown to mediate inter-
nalization of MT1-MMP from the cell surface to lysosomes, and
MT1-MMP undertakes lysosomal porteolysis. Among tetra-
spanin family members, CD151 in endothelial cells and CD9,
CD81, and TSAN12 in cancer cells were reported to be associ-846ated with regulation of MT1-MMP functions.(48,49) They support
MT1-MMP cell-surface expression and functions including
ECM degradation and MMP-2 activation. The CD151-mediated
functional association of MT1-MMP with integrin a3b1 regu-
lates MT1-MMP membrane compartmentalization, subcellular
localization, and cell-surface concentration as a result in endo-
thelial cells.(48) Since MT1-MMP plays an essential role in
angiogenesis, CD151 may contribute to endothelial homeostasis
through the regulation of MT1-MMP. CD9, CD81, and
TSPAN12 also associate with cell surface molecules including
integrins,(51) which may form specialized membrane structures
for invasion (e.g. lamelipodia, filopodia, and invadopodia) with
MT1-MMP.(52) Tetraspanin-regulated cell surface localization
of MT1-MMP increases the local concentration for focal prote-
olysis within the pericellular environment and leads to efficient
ECM degradation and MMP-2 activation. Further study will be
necessary to elucidate physiological and pathological roles of
tetraspanin-MT1-MMP interaction and functional variations
among tetraspanin family members in terms of MT1-MMP regu-
lation.
Conclusion
TIMP-2 dictates substrate choice of MT1-MMP, either direct
cleavage of substrate or pro-MMP-2 activation. In the absence
of TIMP-2, MT1-MMP mediates only direct cleavage of sub-
strates, but not pro-MMP-2 activation. At an appropriately low
concentration of TIMP-2, both MT1-MMP and MMP-2 acti-
vated by MT1-MMP can exert enzyme activities. Coordinate
action of them induces more efficient tissue degradation and
consequent invasive growth compared with that by MT1-MMP
or MMP-2 alone. MMP-2 was shown to play a pivotal role in
invasive growth of ovarian cancer,(47) in which MT1-MMP
should be involved in not only MMP-2 activation but also ECM
degradation, and cooperate with MMP-2. Broad-spectrum syn-
thetic inhibitors targeting MMP active sites suffered from harm-
ful side effects in clinical testing. Targeting MMP-2 or MMP-2
activation step may not be excessively toxic, and is promising
for the suppression of tumor malignancy.References
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